Opdivo (Nivolumab) plus Yervoy (Ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial

Bristol Myers Squibb, Inc. announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy showed a durable survival benefit compared to four cycles of chemotherapy alone after two years of follow-up in previously untreated patients with advanced non-small cell lung cancer (NSCLC).